Cargando…

Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic

Chronic infection with hepatitis B and delta viruses (HDV) is the most serious form of viral hepatitis due to more severe manifestations of an accelerated progression to liver fibrosis, cirrhosis, and hepatocellular carcinoma. We characterized early HDV kinetics post-inoculation and incorporated mat...

Descripción completa

Detalles Bibliográficos
Autores principales: Maya, Stephanie, Hershkovich, Leeor, Cardozo-Ojeda, E. Fabian, Shirvani-Dastgerdi, Elham, Srinivas, Jay, Shekhtman, Louis, Uprichard, Susan L., Berneshawi, Andrew R., Cafiero, Thomas R., Dahari, Harel, Ploss, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470517/
https://www.ncbi.nlm.nih.gov/pubmed/37436080
http://dx.doi.org/10.1128/mbio.01008-23
_version_ 1785099695663611904
author Maya, Stephanie
Hershkovich, Leeor
Cardozo-Ojeda, E. Fabian
Shirvani-Dastgerdi, Elham
Srinivas, Jay
Shekhtman, Louis
Uprichard, Susan L.
Berneshawi, Andrew R.
Cafiero, Thomas R.
Dahari, Harel
Ploss, Alexander
author_facet Maya, Stephanie
Hershkovich, Leeor
Cardozo-Ojeda, E. Fabian
Shirvani-Dastgerdi, Elham
Srinivas, Jay
Shekhtman, Louis
Uprichard, Susan L.
Berneshawi, Andrew R.
Cafiero, Thomas R.
Dahari, Harel
Ploss, Alexander
author_sort Maya, Stephanie
collection PubMed
description Chronic infection with hepatitis B and delta viruses (HDV) is the most serious form of viral hepatitis due to more severe manifestations of an accelerated progression to liver fibrosis, cirrhosis, and hepatocellular carcinoma. We characterized early HDV kinetics post-inoculation and incorporated mathematical modeling to provide insights into host-HDV dynamics. We analyzed HDV RNA serum viremia in 192 immunocompetent (C57BL/6) and immunodeficient (NRG) mice that did or did not transgenically express the HDV receptor—human sodium taurocholate co-transporting polypeptide (hNTCP). Kinetic analysis indicates an unanticipated biphasic decline consisting of a sharp first-phase and slower second-phase decline regardless of immunocompetence. HDV decline after re-inoculation again followed a biphasic decline; however, a steeper second-phase HDV decline was observed in NRG-hNTCP mice compared to NRG mice. HDV-entry inhibitor bulevirtide administration and HDV re-inoculation indicated that viral entry and receptor saturation are not major contributors to clearance, respectively. The biphasic kinetics can be mathematically modeled by assuming the existence of a non-specific-binding compartment with a constant on/off-rate and the steeper second-phase decline by a loss of bound virus that cannot be returned as free virus to circulation. The model predicts that free HDV is cleared with a half-life of 35 minutes (standard error, SE: 6.3), binds to non-specific cells with a rate of 0.05 per hour (SE: 0.01), and returns as free virus with a rate of 0.11 per hour (SE: 0.02). Characterizing early HDV-host kinetics elucidates how quickly HDV is either cleared or bound depending on the immunological background and hNTCP presence. IMPORTANCE: The persistence phase of HDV infection has been studied in some animal models; however, the early kinetics of HDV in vivo is incompletely understood. In this study, we characterize an unexpectedly HDV biphasic decline post-inoculation in immunocompetent and immunodeficient mouse models and use mathematical modeling to provide insights into HDV-host dynamics.
format Online
Article
Text
id pubmed-10470517
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-104705172023-09-01 Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic Maya, Stephanie Hershkovich, Leeor Cardozo-Ojeda, E. Fabian Shirvani-Dastgerdi, Elham Srinivas, Jay Shekhtman, Louis Uprichard, Susan L. Berneshawi, Andrew R. Cafiero, Thomas R. Dahari, Harel Ploss, Alexander mBio Research Article Chronic infection with hepatitis B and delta viruses (HDV) is the most serious form of viral hepatitis due to more severe manifestations of an accelerated progression to liver fibrosis, cirrhosis, and hepatocellular carcinoma. We characterized early HDV kinetics post-inoculation and incorporated mathematical modeling to provide insights into host-HDV dynamics. We analyzed HDV RNA serum viremia in 192 immunocompetent (C57BL/6) and immunodeficient (NRG) mice that did or did not transgenically express the HDV receptor—human sodium taurocholate co-transporting polypeptide (hNTCP). Kinetic analysis indicates an unanticipated biphasic decline consisting of a sharp first-phase and slower second-phase decline regardless of immunocompetence. HDV decline after re-inoculation again followed a biphasic decline; however, a steeper second-phase HDV decline was observed in NRG-hNTCP mice compared to NRG mice. HDV-entry inhibitor bulevirtide administration and HDV re-inoculation indicated that viral entry and receptor saturation are not major contributors to clearance, respectively. The biphasic kinetics can be mathematically modeled by assuming the existence of a non-specific-binding compartment with a constant on/off-rate and the steeper second-phase decline by a loss of bound virus that cannot be returned as free virus to circulation. The model predicts that free HDV is cleared with a half-life of 35 minutes (standard error, SE: 6.3), binds to non-specific cells with a rate of 0.05 per hour (SE: 0.01), and returns as free virus with a rate of 0.11 per hour (SE: 0.02). Characterizing early HDV-host kinetics elucidates how quickly HDV is either cleared or bound depending on the immunological background and hNTCP presence. IMPORTANCE: The persistence phase of HDV infection has been studied in some animal models; however, the early kinetics of HDV in vivo is incompletely understood. In this study, we characterize an unexpectedly HDV biphasic decline post-inoculation in immunocompetent and immunodeficient mouse models and use mathematical modeling to provide insights into HDV-host dynamics. American Society for Microbiology 2023-07-12 /pmc/articles/PMC10470517/ /pubmed/37436080 http://dx.doi.org/10.1128/mbio.01008-23 Text en Copyright © 2023 Maya et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Maya, Stephanie
Hershkovich, Leeor
Cardozo-Ojeda, E. Fabian
Shirvani-Dastgerdi, Elham
Srinivas, Jay
Shekhtman, Louis
Uprichard, Susan L.
Berneshawi, Andrew R.
Cafiero, Thomas R.
Dahari, Harel
Ploss, Alexander
Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic
title Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic
title_full Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic
title_fullStr Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic
title_full_unstemmed Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic
title_short Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic
title_sort hepatitis delta virus rna decline post-inoculation in human ntcp transgenic mice is biphasic
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470517/
https://www.ncbi.nlm.nih.gov/pubmed/37436080
http://dx.doi.org/10.1128/mbio.01008-23
work_keys_str_mv AT mayastephanie hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT hershkovichleeor hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT cardozoojedaefabian hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT shirvanidastgerdielham hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT srinivasjay hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT shekhtmanlouis hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT uprichardsusanl hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT berneshawiandrewr hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT cafierothomasr hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT dahariharel hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic
AT plossalexander hepatitisdeltavirusrnadeclinepostinoculationinhumanntcptransgenicmiceisbiphasic